Literature DB >> 30015228

Associations between complement pathways activity, mannose-binding lectin, and odds of unprovoked venous thromboembolism.

Ina Isabella Høiland1, Robin Amanda Liang2, Kristian Hindberg2, Nadezhda Latysheva3, Ole-Lars Brekke4, Tom Eirik Mollnes5, John-Bjarne Hansen3.   

Abstract

INTRODUCTION: Deep vein thrombosis (DVT) originates in the valvular sinuses of large veins in a local milieu characterized by stasis and severe hypoxia. This may induce complement- and coagulation activation, which potentially increases the risk of venous thromboembolism (VTE). The aim of the present study was to investigate whether the activity of the complement pathways, the level of mannose-binding lectin (MBL) and tissue-factor (TF) induced thrombin generation were associated with risk of unprovoked VTE.
METHODS: A case-control study was performed in patients with unprovoked VTE (n = 24) and age- and sex-matched healthy controls (n = 24). Serum complement pathway activity was measured by the total complement screen assay (Wieslab®). MBL was quantified by ELISA. Plasma TF-induced thrombin generation was measured using the CAT-assay.
RESULTS: Activity in the highest quintile of the classical pathway was associated with increased odds of unprovoked VTE (OR 4.5, 95% CI; 0.8-24.7). Moreover, MBL deficiency (≤100 ng/ml) was associated with unprovoked VTE (OR 3.5, 95% Cl; 0.8-15.3). VTE patients had shortened TF-induced lag-time (4.8 ± 0.6 min vs. 5.8 ± 2.1 min, p < 0.001) and a higher endogenous thrombin potential (ETP) (1383 ± 267 nM∗h vs. 1265 ± 247 nM∗h, p = 0.07) than controls. No association between the classical complement pathway activity or MBL deficiency, and parameters of TF-induced thrombin generation was observed.
CONCLUSION: Our findings suggest that high activity of the classical complement pathway, and MBL deficiency, might be associated with an increased odds of unprovoked VTE, independent of activation of TF-induced coagulation.
Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Complement; Thrombin generation; Tissue factor; Venous thrombosis

Mesh:

Substances:

Year:  2018        PMID: 30015228     DOI: 10.1016/j.thromres.2018.06.019

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Tackling Neuroinflammation After Traumatic Brain Injury: Complement Inhibition as a Therapy for Secondary Injury.

Authors:  Inge A M van Erp; Iliana Michailidou; Thomas A van Essen; Mathieu van der Jagt; Wouter Moojen; Wilco C Peul; Frank Baas; Kees Fluiter
Journal:  Neurotherapeutics       Date:  2022-10-12       Impact factor: 6.088

2.  Plasma procoagulant phospholipid clotting time and venous thromboembolism risk.

Authors:  Cathrine Ramberg; Line Wilsgård; Nadezhda Latysheva; Sigrid K Brækkan; Kristian Hindberg; Timofey Sovershaev; Omri Snir; John-Bjarne Hansen
Journal:  Res Pract Thromb Haemost       Date:  2021-12-20

Review 3.  Inflammation in Cerebral Venous Thrombosis.

Authors:  Jiayue Ding; Baoying Song; Xiran Xie; Xaingyu Li; Zhiying Chen; Zhongao Wang; Liqun Pan; Duo Lan; Ran Meng
Journal:  Front Immunol       Date:  2022-04-04       Impact factor: 8.786

4.  First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors.

Authors:  Khanh T Do; Laura Quan Man Chow; Karen Reckamp; Rachel E Sanborn; Howard Burris; Francisco Robert; D Ross Camidge; Conor E Steuer; John H Strickler; Amy Weise; Jennifer M Specht; Martin Gutierrez; Peter Haughney; Shawna Hengel; Christina Louise Derleth; Timothy A Yap
Journal:  Oncologist       Date:  2021-09-22

5.  Complement C1q Enhances Primary Hemostasis.

Authors:  Claudia Donat; Robert Kölm; Kinga Csorba; Eylul Tuncer; Dimitrios A Tsakiris; Marten Trendelenburg
Journal:  Front Immunol       Date:  2020-07-16       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.